Atlas Trials

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

Clinical trial NCT07007962 · RECRUITING

Trial details

NCT number
NCT07007962
Sponsor
Sanofi
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Immune Thrombocytopenia
Start date
2025-10-24
Primary completion
2027-11-05
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.